BACKGROUND: Patients with chronic rhinosinusitis (CRS) have significant quality-of-life (QOL) improvements following endoscopic sinus surgery (ESS). These improvements remain stable and persist between 6 months and 20 months as measured by the Rhinosinusitis Disability Index and the Chronic Sinusitis Survey. There has yet to be an evaluation of the longitudinal stability of the 22-item Sino-Nasal Outcome Test (SNOT-22) after ESS in patients with CRS. METHODS: Adults with medically recalcitrant CRS who were considered surgical candidates were enrolled in a prospective, multicenter, observational cohort study from February 2011 to February 2013. Baseline evaluation of subjects included assessment of clinical characteristics, measures of CRS-specific disease severity, and QOL evaluation using the SNOT-22. Subjects were then re-evaluated at approximately 6-month, 12-month, and 18-month intervals postoperatively. Data was analyzed using repeated measures analysis of variance (ANOVA) with Bonferroni corrections for matched pairwise comparisons. RESULTS: A total of 110 patients completed baseline evaluations and follow-up for all 3 postoperative time points. Significant improvement in SNOT-22 scores was seen between baseline and 6 months across both SNOT-22 total and subdomain scores (p < 0.001). There was no statistically significant difference between the 6-month, 12-month, and 18-month time points in the total SNOT-22 score or its domains (p ≥ 0.125) for both the entire cohort or subgroups (p ≥ 0.077). CONCLUSION: Postoperative improvement in CRS-specific QOL and symptom severity, as measured by the SNOT-22, suggest stability and durability between 6 months and 18 months. Further study on the longitudinal stability of the SNOT-22 past the 18-month time frame will help further refine clinical study of CRS and provide further understanding of temporal improvements following ESS.
BACKGROUND:Patients with chronic rhinosinusitis (CRS) have significant quality-of-life (QOL) improvements following endoscopic sinus surgery (ESS). These improvements remain stable and persist between 6 months and 20 months as measured by the Rhinosinusitis Disability Index and the Chronic Sinusitis Survey. There has yet to be an evaluation of the longitudinal stability of the 22-item Sino-Nasal Outcome Test (SNOT-22) after ESS in patients with CRS. METHODS: Adults with medically recalcitrant CRS who were considered surgical candidates were enrolled in a prospective, multicenter, observational cohort study from February 2011 to February 2013. Baseline evaluation of subjects included assessment of clinical characteristics, measures of CRS-specific disease severity, and QOL evaluation using the SNOT-22. Subjects were then re-evaluated at approximately 6-month, 12-month, and 18-month intervals postoperatively. Data was analyzed using repeated measures analysis of variance (ANOVA) with Bonferroni corrections for matched pairwise comparisons. RESULTS: A total of 110 patients completed baseline evaluations and follow-up for all 3 postoperative time points. Significant improvement in SNOT-22 scores was seen between baseline and 6 months across both SNOT-22 total and subdomain scores (p < 0.001). There was no statistically significant difference between the 6-month, 12-month, and 18-month time points in the total SNOT-22 score or its domains (p ≥ 0.125) for both the entire cohort or subgroups (p ≥ 0.077). CONCLUSION: Postoperative improvement in CRS-specific QOL and symptom severity, as measured by the SNOT-22, suggest stability and durability between 6 months and 18 months. Further study on the longitudinal stability of the SNOT-22 past the 18-month time frame will help further refine clinical study of CRS and provide further understanding of temporal improvements following ESS.
Authors: Timothy L Smith; Robert Kern; James N Palmer; Rodney Schlosser; Rakesh K Chandra; Alexander G Chiu; David Conley; Jess C Mace; Rongwei F Fu; James Stankiewicz Journal: Int Forum Allergy Rhinol Date: 2012-06-26 Impact factor: 3.858
Authors: Adam S DeConde; Jess C Mace; Jeremiah A Alt; Rodney J Schlosser; Timothy L Smith; Zachary M Soler Journal: Int Forum Allergy Rhinol Date: 2014-07-12 Impact factor: 3.858
Authors: Zachary M Soler; Luke Rudmik; Peter H Hwang; Jess C Mace; Rodney J Schlosser; Timothy L Smith Journal: Laryngoscope Date: 2013-07-15 Impact factor: 3.325
Authors: Jeremiah A Alt; Timothy L Smith; Rodney J Schlosser; Jess C Mace; Zachary M Soler Journal: Int Forum Allergy Rhinol Date: 2014-07-30 Impact factor: 3.858
Authors: Adam S DeConde; Jess C Mace; Vijay R Ramakrishnan; Jeremiah A Alt; Timothy L Smith Journal: Laryngoscope Date: 2017-08-04 Impact factor: 3.325
Authors: Waleed M Abuzeid; Jess C Mace; Milena L Costa; Luke Rudmik; Zachary M Soler; Grace S Kim; Timothy L Smith; Peter H Hwang Journal: Int Forum Allergy Rhinol Date: 2016-02-16 Impact factor: 3.858
Authors: Adam S DeConde; Jeffrey D Suh; Jess C Mace; Jeremiah A Alt; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2015-04-23 Impact factor: 3.858
Authors: Daniel M Beswick; Jess C Mace; Luke Rudmik; Zachary M Soler; Adam S DeConde; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2018-07-28 Impact factor: 3.858
Authors: Daniel M Beswick; Jess C Mace; Naweed I Chowdhury; Jeremiah A Alt; Peter H Hwang; Adam S DeConde; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2017-09-22 Impact factor: 3.858
Authors: Daniel M Beswick; Jess C Mace; Zachary M Soler; Noel F Ayoub; Luke Rudmik; Adam S DeConde; Timothy L Smith Journal: Laryngoscope Date: 2018-05-14 Impact factor: 3.325
Authors: Toby O Steele; Kara Y Detwiller; Jess C Mace; E Bradley Strong; Timothy L Smith; Jeremiah A Alt Journal: Laryngoscope Date: 2016-01-09 Impact factor: 3.325